CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $253,276 | +3.6% | 5,580 | +28.2% | 0.01% | -16.7% |
| Q2 2023 | $244,434 | -1.0% | 4,354 | +15.1% | 0.01% | -14.3% |
| Q3 2022 | $247,000 | +2.9% | 3,784 | -4.2% | 0.01% | +16.7% |
| Q2 2022 | $240,000 | -4.4% | 3,951 | -1.0% | 0.01% | 0.0% |
| Q1 2022 | $251,000 | -12.5% | 3,992 | +5.6% | 0.01% | 0.0% |
| Q4 2021 | $287,000 | -28.4% | 3,781 | +5.6% | 0.01% | -40.0% |
| Q3 2021 | $401,000 | -28.9% | 3,581 | +2.7% | 0.01% | -28.6% |
| Q2 2021 | $564,000 | +11.9% | 3,486 | -15.8% | 0.01% | 0.0% |
| Q1 2021 | $504,000 | -21.7% | 4,138 | -1.6% | 0.01% | -26.3% |
| Q4 2020 | $644,000 | +117.6% | 4,205 | +19.0% | 0.02% | +90.0% |
| Q3 2020 | $296,000 | -5.4% | 3,535 | -16.9% | 0.01% | -9.1% |
| Q2 2020 | $313,000 | +40.4% | 4,255 | +16.3% | 0.01% | +22.2% |
| Q4 2019 | $223,000 | +218.6% | 3,660 | +133.1% | 0.01% | +200.0% |
| Q3 2018 | $70,000 | +233.3% | 1,570 | +237.6% | 0.00% | +200.0% |
| Q1 2018 | $21,000 | – | 465 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |